Reviewed clinical summary · Source-linked · Educational use only

Can Normal-BMI Individuals Maintain Diabetes Remission Without Ongoing Treatment?

Hormone Insight visual abstract summarising intermittent calorie restriction and maintained type 2 diabetes remission.
Visual abstract for intermittent calorie restriction and type 2 diabetes remission.

Clinical Bottom Line

A three-year follow-up finds most people who reached diabetes remission via intermittent calorie restriction maintained it without ongoing intervention. PICO summary and commentary.

Summary: In a three-year follow-up of a trial in type 2 diabetes, 75% of those who reached remission and normal BMI through a three-month intermittent calorie-restriction programme maintained remission without ongoing structured intervention, versus none in the control group.

PICO Summary

ElementDetail
PopulationAdults with type 2 diabetes who reached remission and BMI below 24 through an initial dietary intervention.
InterventionThree-month Chinese Medical Nutrition Therapy: six cycles of 5 days at 840 kcal/day then 10 days ad libitum, then 3 years of self-guided guideline-based eating.
ComparisonControl group with no dietary intervention beyond standard care.
OutcomeAt 3 years, 75% of the CMNT group maintained remission versus 0% control. Remission correlated with withdrawal of insulin/insulinotropic agents. Below BMI 24, weight regain did not affect remission. Fewer complications, hospitalisations, and deaths; better quality of life.
RCT Front Endocrinol (Lausanne) · 2026

Intermittent calorie restriction and durable diabetes remission

RCT · type 2 diabetes · 3-year follow-up

Trial design
T2D, remission + BMI <24 Enrolled & assessed RANDOMISED 1:1 CMNT CMNT then self-guided Control Standard care only Diabetes remission maintained at 3 years
Proportion reaching endpoint
vs 0% in control % maintaining remission at 3y 75% CMNT 0% Control ARR+75% absolute
Remission (CMNT)
75%
at 3 years
Remission (control)
0%
at 3 years
Below BMI 24
Remission held
despite weight regain
Complications/deaths
Lower
with CMNT
⬡ Bottom Line

Three-quarters of normal-BMI patients held diabetes remission at three years with no ongoing programme, versus none in control. Striking but open-label, small, and culturally specific, so it needs replication with an active comparator.

Expert Commentary

Durable remission is the prize in type 2 diabetes, and the headline here, three-quarters still in remission at three years with no ongoing structured programme, is genuinely striking, especially the intriguing observation that in those below a BMI of 24 weight regain did not break remission. That hints remission may be more about a metabolic reset than about sustained weight suppression, which would be important if it holds. I read it as cautiously positive while flagging real limits. This is follow-up data, and the contrast of 75% against a flat 0% in controls is so stark that I suspect the control group was never offered an equivalent attempt, which inflates the apparent effect. The programme is also a specific culturally embedded protocol in a particular population, the numbers are modest, and the open-label dietary design cannot be blinded. Can I use this with my patients? In principle yes, it strengthens my confidence that structured intermittent restriction can produce lasting remission in selected motivated patients, with the welcome message that perfect weight maintenance may not be required. I would want replication in a Western cohort with an active comparator before quoting the 75% figure.

References

Wu R, Yang X, Zhou X, et al. Maintained diabetes remission among normal BMI individuals achieved without ongoing intervention: a three-year follow-up study of intermittent calorie restriction. Front Endocrinol (Lausanne). 2026;16:1733840. doi:10.3389/fendo.2025.1733840

Educational use: Hormone Insight is intended for healthcare professionals and learners. Interpret each summary alongside the primary source, local guidance, and patient-specific clinical judgement.

Subscribe now

Welcome to Hormone Insight. Our mission is to support clinical decision-making with accessible, evidence-based insights from recent studies and trials.

© 2024-2026 Hormone Insight. All rights reserved.